Your session is about to expire
← Back to Search
CC-99282 + Obinutuzumab for Chronic Lymphocytic Leukemia
Study Summary
This trial is testing a new drug combo to treat CLL/SLL.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 & 2 trial • 62 Patients • NCT03310619Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had CAR-T or similar therapy less than 4 weeks ago.I have taken a CRBN-modulating drug within the last 4 weeks.I do not have active autoimmune blood disorders.I am able to care for myself and perform daily activities.I do not have any health issues that would stop me from joining the study.I am 18 years old or older.My condition did not improve after 2+ treatments, including a BTK inhibitor.I had a stem cell or bone marrow transplant more than a year ago and don't have ongoing treatment or disease from it.I have ongoing severe diarrhea or nutrient absorption issues not improved with treatment.My condition has progressed to Richter's Syndrome.My spleen is enlarged, measuring at least 14 cm long.My kidneys are functioning well.I am able to get out of my bed or chair and move around.I do not have another cancer that affects my life expectancy or requires treatment that would interfere with the study.My liver is enlarged, measuring at least 20 cm in length.I have been diagnosed with CLL/SLL and need treatment.My platelet count is healthy or acceptable due to my condition, without needing a transfusion recently.I have moderate to severe numbness, tingling, or pain in my hands or feet.I have CLL/SLL that needs treatment and measurable signs of the disease.I have heart problems that affect my daily activities.My white blood cell count is within the required range without medication help.
- Group 1: CC-99282 + obinutuzumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has CC-99282 been accorded regulatory acceptance by the Food and Drug Administration?
"Judging by the limited data on CC-99282's efficacy and safety, our team gave it a score of 1."
Is this research pioneering a new methodology?
"CC-99282 has been under scrutiny since 2014, when Genentech Inc. sponsored a preliminary study involving 40 patients. After successfully completing Phase 1 & 2 trials, CC-99282 is now being researched in over 100 clinical studies throughout 948 cities and 46 nations around the world."
Has CC-99282 been tested through previous research investigations?
"CC-99282 was first tested at UCSD Moores Cancer Center in 2014, with 55 trials having completed thus far. Currently, there are numerous live studies using this drug being conducted across Montreal, Quebec alone."
To what capacity is this clinical trial accepting new participants?
"Indeed, the clinical trial is presently recruiting. According to records stored on clinicaltrials.gov, it was first posted on December 21st 2020 and most recently modified on October 11th 2022. This study needs to recruit a total of 50 individuals from 9 distinct sites for participation."
How many venues are currently hosting this research effort?
"Patients can find enrolment opportunities at Sir Mortimer B. Davis - Jewish Genl in Montreal, Quebec; Dana Farber Cancer Institute in Boston, Massachusetts; University of Cincinnati Medical Center in Cincinnati, Ohio and an additional 9 sites."
What is the primary goal of this clinical investigation?
"The purpose of this 28-day cycle research is to assess Dose Limiting Toxicity. Secondary metrics include Apparent volume of distribution during terminal phase after non-intravenous administration, Terminal-phase elimination half-life and Pharmacokinetics - V/F."
Is this trial still taking on new participants?
"According to clinicaltrials.gov, the current iteration of this research project is still recruiting participants. The trial first launched on December 21st 2020 and was recently updated on October 11th 2022."
Share this study with friends
Copy Link
Messenger